---
title: "Athira Pharma | 8-K: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264724326.md"
datetime: "2025-11-06T21:36:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264724326.md)
  - [en](https://longbridge.com/en/news/264724326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264724326.md)
generator: "portal-rs"
---

# Athira Pharma | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.68, missing the estimate of USD -1.22.

### Financial Results

#### Cash Position

-   Cash, cash equivalents, and investments were $25.2 million as of September 30, 2025, compared to $51.3 million as of December 31, 2024.
-   Net cash used in operations was $26.3 million for the nine months ended September 30, 2025, compared to $71.2 million for the nine months ended September 30, 2024.

#### Research and Development (R&D) Expenses

-   R&D expenses were $2.8 million for the quarter ended September 30, 2025, compared to $17.9 million for the quarter ended September 30, 2024.

#### General and Administrative (G&A) Expenses

-   G&A expenses were $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024.

#### Net Loss

-   Net loss was $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025, compared to a net loss of $28.7 million, or $7.46 per share (on a split-adjusted basis), for the quarter ended September 30, 2024.

### Outlook / Guidance

-   Athira Pharma continues to explore strategic alternatives focusing on maximizing stockholder value.
-   The company remains encouraged by the promising data supporting the continued development of ATH-1105 as a potential therapy for ALS.
-   Athira plans to advance the ATH-1105 program into ALS patients to bring a potential novel therapy to those in need of an effective treatment option.

### Related Stocks

- [ATHA.US](https://longbridge.com/en/quote/ATHA.US.md)
- [LONA.US](https://longbridge.com/en/quote/LONA.US.md)

## Related News & Research

- [LeonaBio Q2 net loss widens on higher R&D spending](https://longbridge.com/en/news/295971106.md)
- [LeonaBio targets Phase 3 ELAINE-3 enrollment completion in Q4 2026, topline data seen in H2 2027](https://longbridge.com/en/news/295655741.md)
- [LeonaBio spotlights lasofoxifene at DAVA Oncology breast cancer summit](https://longbridge.com/en/news/295654419.md)
- [Queen’s Road Capital publishes MD&A for nine months ended May 31, 2026](https://longbridge.com/en/news/292480941.md)
- [LeonaBio stockholders back Ernst & Young as 2026 auditor at annual meeting](https://longbridge.com/en/news/290603553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**